| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Pfizer Inc. | Brepocitinib - (VALOR) | Dermatomyositis (DM) | NDA Filing | Ongoing | Oral | Immunology |
| Pfizer Inc. | Tanezumab | Osteoarthritis | NDA Filing | Withdrawn | Subcutaneous | Orthopedic |
| Pfizer Inc. | Sasanlimab - (CREST) | Non-Muscle Invasive Bladder Cancer | NDA Filing | Data Released | Subcutaneous | Oncology |
| Pfizer Inc. | Sasanlimab - (CREST) | Non-Muscle Invasive Bladder Cancer | NDA Filing | Data Released | Subcutaneous | Oncology |
| Pfizer Inc. | Sasanlimab - (CREST) | Non-Muscle Invasive Bladder Cancer | NDA Filing | Data Released | Subcutaneous | Oncology |
| Pfizer Inc. | Sasanlimab - (CREST) | Non-Muscle Invasive Bladder Cancer | NDA Filing | Data Released | Subcutaneous | Oncology |
| Pfizer Inc. | XTANDI (enzalutamide) - (EMBARK) | Prostate Cancer | Phase 3 | Data Released | Oral | Oncology |
| Pfizer Inc. | VLA15 - (VALOR) | Lyme disease vaccine for outdoor recreationists | Phase 3 | Ongoing | Intramuscular | Immunology |